Orca Bio Inc. reported at the American Society of Hematology that cancer patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) who received its Orca-T cell therapy product achieved higher rates of survival without experiencing either relapse or chronic graft-vs.-host (GvHD) disease than those who received a conventional graft.